Aptose Biosciences (TSE:APS) Stock Price Passes Above Fifty Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of C$2.21 and traded as high as C$2.24. Aptose Biosciences shares last traded at C$2.23, with a volume of 10,000 shares trading hands.

Analysts Set New Price Targets

Separately, Alliance Global Partners lowered Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Aptose Biosciences Price Performance

The company has a debt-to-equity ratio of -97.77, a quick ratio of 5.41 and a current ratio of 0.53. The company’s 50 day moving average price is C$2.21 and its 200-day moving average price is C$2.02. The company has a market cap of C$5.69 million, a price-to-earnings ratio of 3.23 and a beta of -1.19.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.